Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Amir T. Fathi(University of Southern California), Olga Salamero(Vall d'Hebron Institut de Recerca), Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Stephen Dale(Kura Oncology (United States)), Mithun Vinod Shah(Mayo Clinic in Arizona), Julie Mackey Ahsan(Kura Oncology (United States)), Pierre Péterlin(Hotel Dieu Hospital), Jessica K. Altman(Northwestern University), Amitava Mitra(Kura Oncology (United States)), James M. Foran(Memorial Sloan Kettering Cancer Center), Daniel Corum(Fujikura (United States)), Gary J. Schiller(Fred Hutch Cancer Center), Joshua Ray(University of Michigan), Harris S. Soifer(Kura Oncology (United States)), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Brian M. Linhares(University of Michigan), Kun Nie(Kura Oncology (United States)), Michael R. Savona(Vanderbilt University), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Marilyn Tabachri(Kura Oncology (United States)), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Kristen Pettit(University of Michigan), Eduardo Rodríguez‐Arbolí(Instituto de Biomedicina de Sevilla), Marina Kremyanskaya(Tisch Cancer Institute), Mrinal M. Patnaik(Mayo Clinic), Tomasz Cierpicki(University of Michigan), Jolanta Grembecka(University of Michigan), Céline Berthon(Université Paris-Sud), Bradley Clegg(University of Michigan), Mollie Leoni(Kura Oncology (United States)), Lionel Adès(Centre National de la Recherche Scientifique), Pau Montesinos(Instituto de Salud Carlos III), Stephane DeBotton(Institut Gustave Roussy), Maël Heiblig(Université Claude Bernard Lyon 1)
Cited by 106
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k